Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Recruiting

Phase 2

NemtabrutinibEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT04728893

Conditions

Hematologic Malignancies

Waldenstroms Macroglobulinaemia

Non-Hodgkins Lymphoma

Chronic Lymphocytic Leukaemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Nemtabrutinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-17. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-11-10.